DiaSorin Molecular Simplexa® Influenza A H1N1 Kit

Simplexa™ Influenza A H1N1 (2009) Kit

Target, identify and differentiate H1N1 in your lab

Do you want to place an order or request a trial?

Discover More

KIT for Infectious Diseases

Overview

Background

While the initial threat to world health has been alleviated, H1N1 is different from other flu A viruses and may challenge health care professionals and organizations for years to come. Which is why reliable detection by molecular testing continues to be extremely important especially for higher-risk patient populations.

Why to choose it

Quickly and accurately detect and differentiate H1N1 in your lab.

For use on

LIAISON^® MDX

Universal Disc

Benefits

Reliability

Reliable Performance

100% positive agreement

100% positive agreement for the H1N1 and influenza A virus.

Agreement with composite reference method¹

2009 H1N1 Clinical Agreement

Agreement with composite reference method¹	Swabs²	Aspirates²
Agreement with composite reference method¹Percent Positive Agreement Percent Negative Agreement	Swabs²100% 95.5%	Aspirates²100% 92.5%

Influenza A Clinical Agreement

Agreement with composite reference method¹	Swabs²	Aspirates²
Agreement with composite reference method¹Percent Positive Agreement Percent Negative Agreement	Swabs²100% 92.5%	Aspirates²100% 96.1%
¹Specimens were determined to be positive for 2009 H1N1 influenza by a composite reference method for the Flu A target including the Luminex xTAG RVP Flu A target, a validated PCR assay using primer and probe sequences published by the CDC and a well characterized PCR followed by sequencing. ²Prospectively collected samples. 299 prospectively collected nasal/nasopharyngeal swabs and 112 nasopharyngeal aspirates were analyzed.